Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment

[1] Weidinger S(2018)Atopic dermatitis Nat Rev Dis Primers 4 1-28.e2

[2] Beck LA(2021)Atopic dermatitis in the pediatric population: a cross-sectional, international, epidemiologic study Ann Allergy Asthma Immunol 126 417-1293

[3] Bieber T(2018)Epidemiology of atopic dermatitis in adults: results from an international survey Allergy 73 1284-437

[4] Kabashima K(2017)Commonality of the IL-4/IL-13 pathway in atopic diseases Expert Rev Clin Immunol 13 425-1204

[5] Irvine AD(2020)Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation Allergy 75 1188-1101

[6] Silverberg JI(2018)Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) Br J Dermatol 178 1083-2303

[7] Barbarot S(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 389 2287-2348

[8] Gadkari A(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-577

[9] Barbarot S(2020)Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis Am J Clin Dermatol 21 567-2379

[10] Auziere S(2020)Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry Allergy 75 2376-143

[1] Weidinger S(2018)Atopic dermatitis Nat Rev Dis Primers 4 1-28.e2

[2] Beck LA(2021)Atopic dermatitis in the pediatric population: a cross-sectional, international, epidemiologic study Ann Allergy Asthma Immunol 126 417-1293

[3] Bieber T(2018)Epidemiology of atopic dermatitis in adults: results from an international survey Allergy 73 1284-437

[4] Kabashima K(2017)Commonality of the IL-4/IL-13 pathway in atopic diseases Expert Rev Clin Immunol 13 425-1204

[5] Irvine AD(2020)Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation Allergy 75 1188-1101

[6] Silverberg JI(2018)Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) Br J Dermatol 178 1083-2303

[7] Barbarot S(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 389 2287-2348

[8] Gadkari A(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-577

[9] Barbarot S(2020)Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis Am J Clin Dermatol 21 567-2379

[10] Auziere S(2020)Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry Allergy 75 2376-143